Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron. Structure Therapeutics' stock soared toward an 18-month high in early Monday trading, after mid-stage data for its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback